Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
Open Access
- 17 April 2023
- journal article
- research article
- Published by Springer Nature in npj Breast Cancer
- Vol. 9 (1) , 1-5
Abstract
Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting.Keywords
This publication has 17 references indexed in Scilit:
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerNew England Journal of Medicine, 2022
- Prognostic Significance of Low HER2 Expression in Patients With Early Hormone Receptor Positive Breast CancerCancer Diagnosis & Prognosis, 2022
- Clinical Review on the Management of Hormone Receptor–Positive Metastatic Breast CancerJCO Oncology Practice, 2022
- Abstract P5-13-24: Efficacy of first line CDK4/6 inhibitors in HER2-low vs HER2-zero, hormone receptor positive, HER2 negative metastatic breast cancerCancer Research, 2022
- The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast CancerJAMA Network Open, 2021
- Evolution of HER2-low expression from primary to recurrent breast cancernpj Breast Cancer, 2021
- Prognostic impact of HER2-low expression in hormone receptor positive early breast cancerThe Breast, 2021
- Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trialsThe Lancet Oncology, 2021
- Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancernpj Breast Cancer, 2021
- HER2-Low Breast Cancer: Pathological and Clinical LandscapeJournal of Clinical Oncology, 2020